NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









jCyte, Inc.

jCyte, Inc.

Private
Newport Beach, CaliforniaHealthcare & Life Scienceshttps://www.jcyte.com/

Last Round

Convertible Debt

May 8, 2020

Total Funding Raised

$47.91M

Company Overview

jCyte, Inc. is a drug discovery company that develops cell-based therapeutics intended to cure degenerative retinal disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

retinitis pigmentosacell therapyRPgene-agnostic therapyregenerative medicineallogeneic cell therapyclinical stage biotechretinal progenitor cellsvision restorationhRPCsvision loss treatmentstem cell therapyRMATintravitreal injectionRegenerative Medicine Advanced Therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

jCyte, Inc. Comparables

Compare jCyte, Inc. with similar companies based on industry and business-model similarity.

jCyte, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
InGel Therapeutics
83%
Nanoscope Therapeutics Inc.
83%
SparingVision
81%

jCyte, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtMay 8, 2020
GrantApr 13, 2020
Series AApr 1, 2019
GrantDec 13, 2016
GrantSep 17, 2012

Key People

Founding team and executive leadership

Jing Yang

Co-Founder & Chief Scientific Officer

Founding Team

John Sholar

Chief Executive Officer

Executive Team

jCyte, Inc. Investors

Notable investors and investment history

jCyte, Inc. investors
InvestorRounds
California Institute for Regenerative MedicineGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2026

    Monthly visitors grew 63% MoM, reaching 2.5K.

  • Jan 2, 2026

    Monthly visitors increased 200% MoM, reaching 4.6K.

jCyte, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

jCyte, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about jCyte, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersNewport Beach, California
Employee Range11
Year Founded2010
Last FundingMay 8, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.